Gold nanoparticles conjugated with anti-CD133 monoclonal antibody and 5-fluorouracil chemotherapeutic agent as nanocarriers for cancer cell targeting

The enhanced permeability and retention effect allows for passive targeting of solid tumours by nanoparticles carrying anticancer drugs. However, active targeting by incorporation of various ligands onto nanoparticles can provide for a more selective and enhanced chemotherapeutic effect and compleme...

Full description

Bibliographic Details
Main Authors: Mohd-Zahid, Manali Haniti, Zulkifli, Siti Nadiah, Che Abdullah, Che Azurahanim, Lim, Jit Kang, Fakurazi, Sharida, Kah, Keng Wong, Zakaria, Andee Dzulkarnaen, Ismail, Norzila, Uskoković, Vuk, Mohamud, Rohimah, Zakaria, Zukarnain
Format: Article
Language:English
Published: RSC Publishing 2021
Online Access:http://psasir.upm.edu.my/id/eprint/97460/1/ABSTRACT.pdf
_version_ 1825937871473737728
author Mohd-Zahid, Manali Haniti
Zulkifli, Siti Nadiah
Che Abdullah, Che Azurahanim
Lim, Jit Kang
Fakurazi, Sharida
Kah, Keng Wong
Zakaria, Andee Dzulkarnaen
Ismail, Norzila
Uskoković, Vuk
Mohamud, Rohimah
Zakaria, Zukarnain
author_facet Mohd-Zahid, Manali Haniti
Zulkifli, Siti Nadiah
Che Abdullah, Che Azurahanim
Lim, Jit Kang
Fakurazi, Sharida
Kah, Keng Wong
Zakaria, Andee Dzulkarnaen
Ismail, Norzila
Uskoković, Vuk
Mohamud, Rohimah
Zakaria, Zukarnain
author_sort Mohd-Zahid, Manali Haniti
collection UPM
description The enhanced permeability and retention effect allows for passive targeting of solid tumours by nanoparticles carrying anticancer drugs. However, active targeting by incorporation of various ligands onto nanoparticles can provide for a more selective and enhanced chemotherapeutic effect and complement the deficiencies of the passive targeting approach. Here we report on the design of the carboxyl-terminated PEGylated gold nanoparticles (AuNPs), their functionalization with anti-CD133 monoclonal antibody (mAb) via a crosslinking reaction, and subsequent 5-fluorouracil (5-FU) drug loading. The synthesized products in the form of stable colloids were characterised using a range of physicochemical techniques, including X-ray diffraction (XRD), UV-Vis spectroscopy, transmission electron microscopy (TEM), and dynamic light scattering (DLS). Conjugation of anti-CD133 mAb onto PEGylated AuNPs was confirmed with the use of UV-Vis, BCA protein assay and fluorescence microscopy. HCT116 colorectal cancer cells abundantly expressed CD133: 92.4 ± 1.3%, as measured by flow cytometry. Whereas PEGylated AuNPs not conjugated with anti-CD133 mAb accumulated mainly at the cellular membrane, nanoparticles conjugated with anti-CD133 mAb were contained within the nuclear region of the cells. Anti-CD133 mAb conjugation facilitated the specific intracellular uptake due to specific antigen–antibody binding interaction. In vitro cytotoxicity studies on HCT116 cells showed that PEGylated AuNPs and PEGylated AuNPs-CD133 did not elicit any toxicity at any of the tested concentrations. Meanwhile, 5-FU-PEGylated AuNPs-CD133 significantly reduced the cell viability relative to the treatment with 5-FU-PEGylated AuNPs without anti-CD133 mAb conjugates (p < 0.0001). This study shows that the conjugation of nanocarriers with the anti-CD133 antibody improves the specific targeting of 5-FU against colorectal cancer cells. These results demonstrate that simultaneous functionalisation of PEGylated AuNPs with antibodies and chemotherapeutic drugs is a viable strategy to combat cancer through targeted drug delivery.
first_indexed 2024-03-06T11:05:59Z
format Article
id upm.eprints-97460
institution Universiti Putra Malaysia
language English
last_indexed 2024-03-06T11:05:59Z
publishDate 2021
publisher RSC Publishing
record_format dspace
spelling upm.eprints-974602022-07-27T08:44:52Z http://psasir.upm.edu.my/id/eprint/97460/ Gold nanoparticles conjugated with anti-CD133 monoclonal antibody and 5-fluorouracil chemotherapeutic agent as nanocarriers for cancer cell targeting Mohd-Zahid, Manali Haniti Zulkifli, Siti Nadiah Che Abdullah, Che Azurahanim Lim, Jit Kang Fakurazi, Sharida Kah, Keng Wong Zakaria, Andee Dzulkarnaen Ismail, Norzila Uskoković, Vuk Mohamud, Rohimah Zakaria, Zukarnain The enhanced permeability and retention effect allows for passive targeting of solid tumours by nanoparticles carrying anticancer drugs. However, active targeting by incorporation of various ligands onto nanoparticles can provide for a more selective and enhanced chemotherapeutic effect and complement the deficiencies of the passive targeting approach. Here we report on the design of the carboxyl-terminated PEGylated gold nanoparticles (AuNPs), their functionalization with anti-CD133 monoclonal antibody (mAb) via a crosslinking reaction, and subsequent 5-fluorouracil (5-FU) drug loading. The synthesized products in the form of stable colloids were characterised using a range of physicochemical techniques, including X-ray diffraction (XRD), UV-Vis spectroscopy, transmission electron microscopy (TEM), and dynamic light scattering (DLS). Conjugation of anti-CD133 mAb onto PEGylated AuNPs was confirmed with the use of UV-Vis, BCA protein assay and fluorescence microscopy. HCT116 colorectal cancer cells abundantly expressed CD133: 92.4 ± 1.3%, as measured by flow cytometry. Whereas PEGylated AuNPs not conjugated with anti-CD133 mAb accumulated mainly at the cellular membrane, nanoparticles conjugated with anti-CD133 mAb were contained within the nuclear region of the cells. Anti-CD133 mAb conjugation facilitated the specific intracellular uptake due to specific antigen–antibody binding interaction. In vitro cytotoxicity studies on HCT116 cells showed that PEGylated AuNPs and PEGylated AuNPs-CD133 did not elicit any toxicity at any of the tested concentrations. Meanwhile, 5-FU-PEGylated AuNPs-CD133 significantly reduced the cell viability relative to the treatment with 5-FU-PEGylated AuNPs without anti-CD133 mAb conjugates (p < 0.0001). This study shows that the conjugation of nanocarriers with the anti-CD133 antibody improves the specific targeting of 5-FU against colorectal cancer cells. These results demonstrate that simultaneous functionalisation of PEGylated AuNPs with antibodies and chemotherapeutic drugs is a viable strategy to combat cancer through targeted drug delivery. RSC Publishing 2021 Article PeerReviewed text en http://psasir.upm.edu.my/id/eprint/97460/1/ABSTRACT.pdf Mohd-Zahid, Manali Haniti and Zulkifli, Siti Nadiah and Che Abdullah, Che Azurahanim and Lim, Jit Kang and Fakurazi, Sharida and Kah, Keng Wong and Zakaria, Andee Dzulkarnaen and Ismail, Norzila and Uskoković, Vuk and Mohamud, Rohimah and Zakaria, Zukarnain (2021) Gold nanoparticles conjugated with anti-CD133 monoclonal antibody and 5-fluorouracil chemotherapeutic agent as nanocarriers for cancer cell targeting. RSC Advances, 11 (26). 16131 - 16141. ISSN 2046-2069 https://pubs.rsc.org/en/content/articlelanding/2021/ra/d1ra01093j 10.1039/D1RA01093J
spellingShingle Mohd-Zahid, Manali Haniti
Zulkifli, Siti Nadiah
Che Abdullah, Che Azurahanim
Lim, Jit Kang
Fakurazi, Sharida
Kah, Keng Wong
Zakaria, Andee Dzulkarnaen
Ismail, Norzila
Uskoković, Vuk
Mohamud, Rohimah
Zakaria, Zukarnain
Gold nanoparticles conjugated with anti-CD133 monoclonal antibody and 5-fluorouracil chemotherapeutic agent as nanocarriers for cancer cell targeting
title Gold nanoparticles conjugated with anti-CD133 monoclonal antibody and 5-fluorouracil chemotherapeutic agent as nanocarriers for cancer cell targeting
title_full Gold nanoparticles conjugated with anti-CD133 monoclonal antibody and 5-fluorouracil chemotherapeutic agent as nanocarriers for cancer cell targeting
title_fullStr Gold nanoparticles conjugated with anti-CD133 monoclonal antibody and 5-fluorouracil chemotherapeutic agent as nanocarriers for cancer cell targeting
title_full_unstemmed Gold nanoparticles conjugated with anti-CD133 monoclonal antibody and 5-fluorouracil chemotherapeutic agent as nanocarriers for cancer cell targeting
title_short Gold nanoparticles conjugated with anti-CD133 monoclonal antibody and 5-fluorouracil chemotherapeutic agent as nanocarriers for cancer cell targeting
title_sort gold nanoparticles conjugated with anti cd133 monoclonal antibody and 5 fluorouracil chemotherapeutic agent as nanocarriers for cancer cell targeting
url http://psasir.upm.edu.my/id/eprint/97460/1/ABSTRACT.pdf
work_keys_str_mv AT mohdzahidmanalihaniti goldnanoparticlesconjugatedwithanticd133monoclonalantibodyand5fluorouracilchemotherapeuticagentasnanocarriersforcancercelltargeting
AT zulkiflisitinadiah goldnanoparticlesconjugatedwithanticd133monoclonalantibodyand5fluorouracilchemotherapeuticagentasnanocarriersforcancercelltargeting
AT cheabdullahcheazurahanim goldnanoparticlesconjugatedwithanticd133monoclonalantibodyand5fluorouracilchemotherapeuticagentasnanocarriersforcancercelltargeting
AT limjitkang goldnanoparticlesconjugatedwithanticd133monoclonalantibodyand5fluorouracilchemotherapeuticagentasnanocarriersforcancercelltargeting
AT fakurazisharida goldnanoparticlesconjugatedwithanticd133monoclonalantibodyand5fluorouracilchemotherapeuticagentasnanocarriersforcancercelltargeting
AT kahkengwong goldnanoparticlesconjugatedwithanticd133monoclonalantibodyand5fluorouracilchemotherapeuticagentasnanocarriersforcancercelltargeting
AT zakariaandeedzulkarnaen goldnanoparticlesconjugatedwithanticd133monoclonalantibodyand5fluorouracilchemotherapeuticagentasnanocarriersforcancercelltargeting
AT ismailnorzila goldnanoparticlesconjugatedwithanticd133monoclonalantibodyand5fluorouracilchemotherapeuticagentasnanocarriersforcancercelltargeting
AT uskokovicvuk goldnanoparticlesconjugatedwithanticd133monoclonalantibodyand5fluorouracilchemotherapeuticagentasnanocarriersforcancercelltargeting
AT mohamudrohimah goldnanoparticlesconjugatedwithanticd133monoclonalantibodyand5fluorouracilchemotherapeuticagentasnanocarriersforcancercelltargeting
AT zakariazukarnain goldnanoparticlesconjugatedwithanticd133monoclonalantibodyand5fluorouracilchemotherapeuticagentasnanocarriersforcancercelltargeting